Best Grants for Cancer Nonprofits in Guam

Incyte Corporation, a biopharmaceutical leader, offers healthcare sponsorships to support organizations focused on improving patient care and access to healthcare information. Eligible applicants include medical schools, associations, non-profits, advocacy groups, and hospitals. Requests should align with Incyte's commitment to enhancing the lives of patients affected by cancer and other diseases, ensuring compliance with regulatory guidelines. Organizations must enter a written agreement with Incyte to receive funding.

Incyte Corporation invites organizations to submit membership requests aimed at enhancing healthcare access for patients and advocates. As a biopharmaceutical leader, Incyte supports initiatives that align with its mission to improve patient lives through grants and contributions. Eligible entities include medical schools, associations, non-profits, and advocacy groups. Requests should comply with Incyte's regulatory standards and be submitted at least 60 days prior to the required decision date.

The 2026 Radiation Oncology Institute- Innovation Awards aim to advance cancer treatment by integrating radiation therapy with immunotherapy. Researchers are invited to submit proposals that explore optimal combinations of these modalities to enhance patient outcomes. Funding of up to $100,000 over two years will support projects focused on identifying effective treatment strategies, understanding mechanisms of synergy, and improving access to care. This initiative represents a significant opportunity for innovative research in oncology.

The Radiation Oncology Institute (ROI) Innovation Awards, offered by the American Society for Radiation Oncology, aim to accelerate innovative ideas in radiation therapy. Currently accepting applications for the 2026 awards, the program focuses on optimizing the combination of radiation therapy and immunotherapy to enhance cancer treatment outcomes. By supporting practical research, ROI strives to transform clinical practices and improve patient care in the fight against cancer.

The Joyce Bytof Memorial Cancer Survivors Scholarship, established by Joyce Bytof in collaboration with the American Cancer Society, supports childhood cancer survivors graduating from specific Wisconsin high schools. This scholarship aims to assist them in pursuing higher education despite the financial and academic challenges posed by their experiences. Joyce's legacy continues to inspire hope and resilience among young survivors as they strive for academic success and a brighter future.

The AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant supports innovative research on upper gastrointestinal malignancies, which are responsible for over one million deaths globally in 2023. This grant encourages collaboration between U.S. and Asian institutions, focusing on resistance, metastasis, and novel treatment strategies. Proposals should detail plans for clinical translation and are open to researchers at all career stages, especially those new to upper GI cancer research.

Bristol Myers Squibb Foundation Inc supports independent medical education to enhance healthcare professional competence and improve patient health outcomes. Their mission is to be a global leader in innovative medical education, focusing on evidence-based activities that address critical gaps in knowledge. By fostering excellence in healthcare, they aim to ensure measurable improvements in performance and patient outcomes across various disease areas.

The CORE Funding: AHNS Trainee Pilot Research Award supports innovative research in head and neck oncology, encouraging trainees to engage in clinical or translational studies. Since its inception, CORE has provided over $14 million in grants, facilitating significant advancements in otolaryngology. This initiative aims to enhance research efforts, reduce fragmentation, and promote collaboration among various stakeholders to improve outcomes for patients with head and neck neoplastic diseases.

We are Revolutionaries

Who We Are

We are Revolutionaries -passionate in our singular pursuit of discovering, developing and delivering innovative targeted therapies for patients living with RAS-addicted cancer. At Revolution Medicines, we believe in challenging the status quo to find new therapeutic approaches to some of the toughest cancers. With our first wave of investigational RAS(ON) inhibitors, we are pioneering a new way of targeting the RAS cancer drivers of disease, and we have the potential to change the treatment paradigm in these cancers where there is a significant unmet medical need.

Our mission is to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines.

Research, Grants & Support

At Revolution Medicines, we understand the importance of extending our support of scientific advancement beyond the research we conduct and the medicines we provide.

We support activities that make meaningful information and resources available to the broader medical and scientific communities to help advance science, increase understanding of certain diseases, and enhance patient care.

Charitable Donations

Funding for programs that deliver disease awareness, treatment education, or other healthcare information intended to improve patient understanding and empowerment.

Syndax Pharmaceuticals, Inc.

At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for developing medicines in the field of oncology – one that revolves around collaboration, shared learning, and excellence.

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.

Educational Funding

At Syndax, we are committed to the goal of supporting objective, balanced and scientifically rigorous education that furthers improvements in science, medicine, and patient care. We accomplish this goal, in part, by providing grants for independent medical education (IME) programs. These can include live, online, and/or enduring programs that educate healthcare providers (HCPs), patients, or caregivers. Programs that are funded via Syndax medical education grants must be primarily dedicated, in both effort and time, to medical, health or scientific topics that are objective, balanced, unbiased, and scientifically rigorous. Medical education grants must never be made with the intent to directly or indirectly reward, influence or encourage the recipient to prescribe, purchase, sell or arrange for any Syndax product.

The Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN) Grant, offered by the Patient Advocate Foundation, provides crucial financial assistance to patients facing this cancer type. It covers out-of-pocket healthcare costs, including medication copays and insurance premiums, ensuring those affected can access necessary treatments. With a focus on personalized case management, the foundation has supported millions in navigating their healthcare needs, emphasizing the importance of timely and affordable care for patients diagnosed with MPN.

The AACR June L. Biedler Prize for Cancer Journalism

Prize Summary

The AACR June L. Biedler Prize for Cancer Journalism was established by the AACR in 2015 to raise awareness of the critical role that the media play in educating the public about cancer and cancer research.

Funded by a major bequest to the AACR from cancer research pioneer Dr. June L. Biedler, a scientist, mentor, and former member of the AACR Board of Directors, this prize showcases outstanding examples of cancer journalism and recognizes individual professional journalists who have produced accurate, informative, and compelling stories that enhance the public’s understanding of cancer, cancer research, cancer advocacy, or cancer policy.

The prize provides an unrestricted cash award of $5,000 and a commemorative award.

Categories

Each submission may be considered for only one category, as selected by the candidate on the application form.

Applicants may submit in any of the following categories:

Prize Acceptance

Awardees will be able to accept the prize during the AACR Annual Meeting 2027 in Orlando, April 2-7, 2027.

Gray for Glioblastoma Society

A 501 (c) 3 created to raise awareness for and funds to support Glioblastoma Multiforme research by accepting donations and donating to cancer care and research facilities. Our organization has gifted over $275,000 to support GBM research projects at renowned cancer centers including The Ty Miller Lab at Case Western Reserve University, Dana Farber Cancer Institute, Children’s Hospital LA/Saban Research Institute and The Preston Robert Tisch Brain Tumor Center at Duke. We accomplish this while simultaneously creating a hopeful and positive space and providing resources and a space of community through our social media and events.

Gray for Glioblastoma Grant

Gray for Glioblastoma Society (GFG) is dedicated to funding projects that advance glioblastoma (GBM) research and move the needle forward in care and quality of life. We invite proposals that align with our mission and demonstrate meaningful impact in the GBM space.

St. Baldrick's Foundation

The St. Baldrick's Foundation is a volunteer and donor powered charity committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives. It started with a friendly dare: would you shave your head to raise money for kids’ cancer research? What happened next would change the world. This bold act of baldness has gained major momentum, since its start in 2000. Today, we have more than 1,000 head-shaving events taking place around the world at pubs, restaurants, schools, churches, parks, firehouses, military bases – you name it. It is our constituents’ way of changing the world, in a meaningful way. Volunteers also raise funds through athletic challenges, livestream fundraisers and many other activities.

Since the Foundation's first grants as an independent charity in 2005, St. Baldrick's has invested more than $380 million in childhood cancer research grants worldwide.

About Allied World

Allied World Assurance Company Holdings, Ltd, through its subsidiaries, is a global provider of insurance and reinsurance solutions. The company operates under the brand Allied World and has supported clients, cedents and trading partners with thoughtful service and meaningful coverages since 2001. Since the inception of St. Baldrick’s, Allied World has supported childhood cancer research through the Foundation, and it is the largest of many reinsurance company sponsors, making this life-saving mission a top priority.

Survivorship and Supportive Care Research Grant

These grants are for specific one-year research projects which are hypothesis-driven and focus on areas related to survivorship and supportive care of children and adolescents with cancer. Examples include but are not limited to: studies related to the burden of morbidity, cause-specific mortality, understanding the pathogenesis of treatment-related complications, patient-reported outcomes or quality of life, health communication, health promotion, and psychosocial support across the trajectory from diagnosis to survivorship or end-of-life care.

Projects must have direct applicability and relevance to pediatric cancer. They may be in any discipline of basic, clinical, translational, or epidemiological research.

About the Emporia Community Foundation

Our Mission

To connect caring people with causes that build stronger communities within the Emporia area which includes Chase, Coffey, Greenwood, Lyon, Morris, Osage and Wabaunsee counties.

Choose How You Respond Fund (in memory of Dr. Bryan Douglas) 

The purpose of the Choose How You Respond Fund is to provide funds to qualified individuals to cover expenses related to the treatment of cancer.

About the Emporia Community Foundation

Our Mission

To connect caring people with causes that build stronger communities within the Emporia area which includes Chase, Coffey, Greenwood, Lyon, Morris, Osage and Wabaunsee counties.

Never Let Go Fund

The purpose of the Never Let Go Fund is to provide funds to qualified individuals to cover expenses related to the treatment of childhood cancer. Grant requests will be considered for children under the age of 18.

About Pfizer Grants

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Interventional Research Studies of Brentuximab Vedotin-Based Novel Combinations in AITL and PTCL-NOS

This competitive program is designed to support interventional InvestigatorSponsored Research aimed at generatin clinical evidence for brentuximab vedotin in novel combination approaches in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma–not otherwise specified (PTCL-NOS).

Project Types and Area of Interest

Studies considered for Pfizer support should address key clinical and scientific gaps in the use of brentuximab vedotin in AITL and PTCL-NOS irrrespective of CD30 expression, with a focus on evaluating the safety and efficacy of novel brentuximab vedotin–based combinations with therapies available for PTCL treatment that are supported by a clear scientific rationale grounded in mechanism of action and/or disease biology.

About Us

Children’s Cancer Research Fund is a national nonprofit dedicated to ending childhood cancer. Our main focus is to support the research of bright scientists across the country whose ideas can make the greatest impact for children fighting cancer. We also fund resources and programs that help kids and families as they navigate the difficult experience of cancer treatment and survivorship.

Since 1981, we’ve contributed over $235 million to research, support programs for children and families, and awareness and education outreach. In 2024, over 81 percent of funds raised went directly to these program services areas.

Children’s Cancer Research Fund (CCRF) is a national nonprofit committed to finding safer, more effective therapies for kids battling cancer. Thanks to donors and partners around the country, we have contributed over $235 million to research, education and awareness, and quality-of-life programs for childhood cancer families. We believe kids deserve safer, less toxic treatments, and we’re committed to funding groundbreaking research and services that enhance healing and care.

In 2026, Children’s Cancer Research Fund will focus our research funding efforts on three main areas:

• Hard-to-Treat Cancers
• Survivorship
• Health Disparities

Accelerating Hope: Clinical Trials for Hard-to-Treat Cancers Award

This funding opportunity is limited to support for clinical trials focused on hard-to-treat cancers, prioritizing Phase 0 – Phase 2 studies. Learn more about eligibility criteria and other key details below.

The Healthy After Cancer Award, offered by the Children's Cancer Research Fund, focuses on enhancing the quality of life for childhood cancer survivors. This funding supports research aimed at addressing the long-term effects of cancer therapy, prioritizing survivorship interventions over new treatment development. With a commitment to improving health outcomes for young survivors, this award underscores the importance of addressing unique challenges faced by this population.

The Eliminating Disparities in Childhood Cancers Award, offered by the Children’s Cancer Research Fund, supports innovative research aimed at reducing health disparities in childhood cancer. This initiative prioritizes proposals that identify modifiable risk factors and mechanisms of disparities, emphasizing the importance of improving access to care and treatment outcomes. With over $235 million invested since 1981, CCRF is dedicated to enhancing the quality of life for children and families affected by cancer.

The Accelerating Impact for Hard-to-Treat Cancers Award, offered by the Children's Cancer Research Fund, focuses on pre-clinical research to enhance treatment outcomes for pediatric cancers that are difficult to treat. The award supports innovative studies, including pilot projects and the development of new technologies. As a nonprofit, CCRF has invested over $235 million in initiatives since 1981, aiming to improve therapies and support for children battling cancer, thereby fostering safer and more effective treatment options.

Pershing Square Lotus Award for Ovarian Cancer Research

The Pershing Square Foundation (PSF) has worked across sectors to catalyze innovative approaches to the most difficult problems. Talented individuals have always been at the center of our approach. We aim to support leaders who transform systems, embrace new paradigms, and have an innate drive to make an impact.

PSF has funded pioneering cancer researchers through the Pershing Square Sohn Cancer Research Alliance for over a decade and supported women’s health initiatives in New York City. Through this Request for Proposals (RFP), PSF aims to combine these two priority areas of women’s health and cancer to shine a light on one of the most understudied and underfunded cancers—ovarian cancer. Ovarian cancer is the deadliest gynecologic cancer, with 80% of women diagnosed at an advanced stage. Only 27% of women diagnosed during an advanced stage survive for five years. Ovarian cancer remains a disease with a poor prognosis due to limited early detection and treatment options.

PSF supports research efforts by 

• deploying capital quickly, 
• funding high-risk, high-reward ideas, 
• bringing new perspectives into a field, 
• encouraging collaboration, and 
• leveraging our vast network. We challenge our scientific partners to think creatively and across silos, to spur innovation to fight ovarian cancer.

Through the Pershing Square Lotus Award for Ovarian Cancer Research, PSF is looking for investigators who are either already working on a promising project in ovarian cancer or in another type of cancer that could have an impact on ovarian cancer. Grantees each receive $250,000 a year for three years, totaling $750,000.

Researchers who are not studying ovarian cancer are encouraged to apply and required to find a collaborator with experience in ovarian cancer research.

This award aims to 

• inspire investigators with unique expertise to apply their knowledge to ovarian cancer and 
• empower ovarian cancer researchers to pursue their boldest, most innovative ideas. Facing a disease where too few have survived to-date, PSF ultimately aims to create a culture around ovarian cancer that offers women hope, akin to the breast cancer community. PSF is passionate about changing outcomes for tens of thousands of women a year and is hopeful that future scientific discoveries will allow for more survivors who can share their stories for years to come.

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Patient Travel Grant Program

A mesothelioma diagnosis and treatment often require the patient and their family to incur numerous expenses as part of their treatment. Travel to treatment, alone, can cause a significant financial burden on the patient, which might even cause the patient to not seek treatment away from home, even it’s their best option. To ensure that all patients have the ability to seek specialized help and treatments, the Mesothelioma Applied Research Foundation administers its Travel Grant Program.

The Meso Foundation’s Patient Travel Grant Program, founded by Mary and Bob Cosentino, provides travel grants to patients and one caregiver traveling for an initial consult and/or for clinical trial treatments.

• The type of eligible travel must fall into at least one of these two categories:
  • One trip for one initial consultation with a mesothelioma specialist.
  • Multiple trips to participate in an interventional clinical trial (found on clinicaltrials.gov).

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Bret A. Rosenthal Patient Assistance Fund

Patients diagnosed with cancer at a younger age often face greater financial burdens. This is a time in a patient’s life when they are raising a family, starting a career, or have not accumulated savings. For patients 49 and under, the Foundation administers the Bret A. Rosenthal Patient Assistance Fund grant program. This program is made possible by the generosity of the Rosenthal family.

The CORE Funding: Lilly Research Grant aims to advance research on genetic hearing loss. It invites investigators to explore the genetic factors contributing to hearing loss, promoting innovative projects that enhance understanding in this critical area. Supported by the American Academy of Otolaryngology - Head & Neck Surgery Foundation, the grant fosters significant research efforts to improve outcomes and strategies in otolaryngology, ensuring a comprehensive approach to hearing health.

About Pfizer External Research & Grants

Pfizer External Research & Grants (ER&G) supports independent research, education, and QI initiatives to improve patient outcomes in areas of unmet need. Competitive grants are awarded through transparent RFPs reviewed by independent expert panels.

About ASCP

American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organization for pathologists and laboratory professionals, with more than 100,000 members. ASCP provides excellence in education, certification, and advocacy on behalf of patients and the laboratory workforce. With a portfolio of more than 900 educational activities, ASCP is the worldwide leader in providing CME/CMLE credit for the entire laboratory team.

Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)

The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer Inc. and with participation from the American Society of Clinical Oncology (ASCO, invites proposals for pathology-centric Quality Improvement (QI) initiatives aimed at optimizing molecular testing pathways in the management of metastatic colorectal cancer (mCRC). This grant opportunity seeks to fund sustainable projects that improve biomarker testing practices, strengthen targeted therapy selection, and support care teams in implementing patient-centered protocols. 

The overarching goal of this program is to advance diagnostic excellence and improve treatment decision-making for patients with mCRC.